Moderna (MRNA) Stock Jumps 16% Following Positive Flu Vaccine Results and Wall Street Upgrades

Key Takeaways

Table of Contents

Moderna shares climbed over 16% following the publication of Phase 3 data in the New England Journal of Medicine demonstrating that its mRNA flu vaccine (mRNA-1010) surpassed a standard-dose comparator in participants aged 50 and above.
Following Moderna’s Q1 2026 earnings report, three Wall Street firms boosted their price targets: Evercore ISI raised theirs to $50, Goldman Sachs increased to $49, and Piper Sandler launched coverage with a Buy recommendation.
Headlines about hantavirus cases connected to a cruise voyage from Argentina to Cabo Verde temporarily drew focus to Moderna’s early-phase hantavirus research, though experts emphasize limited commercial potential.
Regulatory authorities have scheduled an August 5 PDUFA target date for mRNA-1010’s FDA review, with additional applications pending in Europe, Canada, and Australia.
Competitors Pfizer and BioNTech discontinued enrollment in a significant U.S. COVID vaccine study for the 50–64 age group due to insufficient participant recruitment.

Shares of Moderna were changing hands near $56 on Thursday, posting gains exceeding 16% during the trading session, propelled by impressive clinical trial outcomes, multiple analyst endorsements, and brief attention surrounding hantavirus developments.

Moderna, Inc., MRNA

The primary catalyst was clear-cut: Phase 3 study outcomes for Moderna’s mRNA-based influenza vaccine, designated mRNA-1010, appeared in the New England Journal of Medicine. The published findings demonstrated the vaccine achieved its predetermined superiority endpoint when compared to a commercially available standard-dose seasonal influenza vaccine among adults 50 years and older.

This represents a significant milestone. Demonstrating superior efficacy against an FDA-approved vaccine in a prestigious peer-reviewed publication strengthens Moderna’s regulatory submission considerably as it approaches a critical agency decision.

Regulatory reviewers at the FDA have designated August 5 as their PDUFA target action date for mRNA-1010. Marketing applications are simultaneously undergoing evaluation in Europe, Canada, and Australia, potentially setting up a coordinated international rollout upon approval.

Wall Street analysts contributed additional momentum to the rally. Evercore ISI increased its price objective from $35 to $50. Goldman Sachs elevated its forecast from $43 to $49. Piper Sandler launched coverage with a Buy recommendation. These revisions all followed Moderna’s first-quarter 2026 financial results.

Hantavirus Story Generated Short-Term Attention

An outbreak of hantavirus affecting travelers aboard a Dutch-registered cruise ship traveling from Argentina to Cabo Verde temporarily boosted Moderna shares during morning trading. Authorities reported eight infections, including three fatalities, with five confirmed as Andes virus — the sole hantavirus variant documented to enable limited person-to-person spread.

The World Health Organization assessed the broader public health threat as minimal. During Thursday’s media briefing, Dr. Maria Van Kerkhove stated unequivocally: “This is not the start of a COVID pandemic.”

Evercore ISI highlighted a research partnership between Moderna and Korea University focused on hantavirus research initiated in 2023, but tempered expectations considerably. The firm stated it anticipates “no meaningful revenue opportunity” stemming from the outbreak coverage and emphasized that Moderna’s hantavirus program “remains very early stage.” The stock, analysts observed, “tends to trade on outbreak headlines well beyond the underlying commercial implications.”

Bottom line: while the hantavirus headlines captured market attention temporarily, the influenza vaccine results and Wall Street endorsements were the genuine drivers behind the share price appreciation.

Cruise Industry Stocks Declined on Health Concerns

Cruise operator equities experienced downward pressure following the hantavirus reports. Royal Caribbean declined approximately 2% during Thursday’s session, while Carnival posted similar losses. Norwegian Cruise Line Holdings dropped nearly 3%. Viking Holdings and Lindblad Expeditions each retreated around 2.5%.

Regarding competitive dynamics, Pfizer and BioNTech discontinued patient recruitment for an extensive U.S. COVID vaccine clinical trial focused on adults between 50 and 64 years old, attributing the decision to inadequate enrollment. This development could potentially strengthen Moderna’s competitive standing in the next-generation vaccine marketplace.

Broader equity markets provided a favorable backdrop, with the S&P 500 advancing 0.71%, the Dow Jones Industrial Average gaining 0.21%, and the Nasdaq Composite rising 1.16%.

Moderna concluded the previous trading session at $48.79. The August 5 FDA regulatory decision regarding mRNA-1010 now represents the company’s next significant near-term event.

✨ Limited Time Offer